[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 3 days · First seen · Last updated

Lobe Sciences sickle cell drug funding

Overview

Lobe Sciences Ltd. has completed a two-tranche non-brokered private placement of common shares, raising a total of $2,160,000. The company issued 25,411,762 shares at a price of $0.085 per share.

The funds are intended for working capital, general corporate purposes, and the advancement of the S-100 drug candidate for the treatment of sickle cell disease. A portion of the proceeds will be allocated to its subsidiary, Applied Lipid Technologies, Inc., to support the S-100 program as it moves toward human clinical trials. The company confirmed it has already procured the active pharmaceutical ingredient necessary for these studies.

Entities

Applied Lipid Technologies, Inc. · Lobe Sciences Ltd. · Canadian Securities Exchange

Timeline

  1. 21 days ago

    [BUSINESS] 2 sources
    Lobe Sciences raises $2.16 million for sickle cell drug development

    Lobe Sciences has raised $2,160,000 through a private placement to fund its S-100 sickle cell disease drug candidate toward human clinical trials.

  2. 24 days ago

    [BUSINESS] 2 sources
    Lobe Sciences upsizes private placement to fund sickle cell drug development

    Lobe Sciences Ltd. is upsizing its non-brokered private placement to raise a total of approximately $2,160,000 to fund its S-100 sickle cell disease drug candidate development.

Sources

digitalmedianet.com · stocktitan.net · webdisclosure.com